Cantor Fitzgerald began coverage on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $24.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on the stock. Cowen and Company reissued an outperform rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Thursday, August 10th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a hold rating to a buy rating and set a $11.00 target price for the company in a research report on Monday, July 10th. BidaskClub lowered shares of Dynavax Technologies Corporation from a buy rating to a hold rating in a research report on Monday, July 31st. William Blair reissued an outperform rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a neutral rating to an overweight rating and boosted their target price for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $24.67.

Shares of Dynavax Technologies Corporation (DVAX) opened at 20.75 on Friday. The firm’s market capitalization is $1.14 billion. The stock’s 50 day moving average price is $17.69 and its 200 day moving average price is $9.68. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $21.85.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.15 million. During the same quarter in the previous year, the business earned ($0.75) EPS. On average, analysts predict that Dynavax Technologies Corporation will post ($1.60) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/19/dynavax-technologies-corporation-dvax-coverage-initiated-at-cantor-fitzgerald.html.

A number of institutional investors have recently added to or reduced their stakes in DVAX. GMT Capital Corp lifted its position in Dynavax Technologies Corporation by 231.5% during the 1st quarter. GMT Capital Corp now owns 2,344,500 shares of the biopharmaceutical company’s stock worth $13,950,000 after acquiring an additional 1,637,300 shares during the last quarter. PointState Capital LP bought a new position in shares of Dynavax Technologies Corporation during the 2nd quarter worth about $13,510,000. Lord Abbett & CO. LLC bought a new position in shares of Dynavax Technologies Corporation during the 2nd quarter worth about $7,777,000. Point72 Asset Management L.P. bought a new position in shares of Dynavax Technologies Corporation during the 1st quarter worth about $4,323,000. Finally, Candriam Luxembourg S.C.A. bought a new position in shares of Dynavax Technologies Corporation during the 2nd quarter worth about $5,066,000. 60.20% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.